Patents by Inventor Edward I. Ginns

Edward I. Ginns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10143684
    Abstract: Methods for treating and diagnosing psychiatric affective disorders, e.g., an affective disorder associated with aberrant Sonic Hedgehog (Shh) signaling, by administering to the subject a therapeutically effective amount of an antagonist to Smoothened (Smo), an antagonist to Patched-1 (Ptch-1) and/or an antagonist to Shh.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: December 4, 2018
    Assignees: University of Massachusetts, University of Miami
    Inventors: Edward I. Ginns, Marzena Galdzicka, Janice A. Egeland
  • Publication number: 20140350066
    Abstract: In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.
    Type: Application
    Filed: November 27, 2013
    Publication date: November 27, 2014
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Edward I. GINNS, Gary R. OSTROFF
  • Patent number: 8637045
    Abstract: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 28, 2014
    Assignee: University of Massachusetts
    Inventors: Edward I. Ginns, Gary R. Ostroff
  • Publication number: 20130065941
    Abstract: In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.
    Type: Application
    Filed: August 13, 2012
    Publication date: March 14, 2013
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Edward I. GINNS, Gary R. OSTROFF
  • Publication number: 20120270206
    Abstract: The invention relates to systems and methods for analyzing clinically relevant nucleic acid sequences.
    Type: Application
    Filed: December 27, 2011
    Publication date: October 25, 2012
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Edward I. Ginns, Marzena Galdzicka
  • Publication number: 20120039929
    Abstract: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.
    Type: Application
    Filed: July 29, 2011
    Publication date: February 16, 2012
    Applicant: University of Massachusetts
    Inventors: Edward I. Ginns, Gary R. Ostroff
  • Patent number: 8007814
    Abstract: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.
    Type: Grant
    Filed: September 19, 2005
    Date of Patent: August 30, 2011
    Assignee: University of Massachusetts
    Inventors: Edward I. Ginns, Gary R. Ostroff
  • Patent number: 7939310
    Abstract: The invention relates to systems and methods for analyzing clinically relevant nucleic acid sequences.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: May 10, 2011
    Assignee: University of Massachusetts
    Inventors: Edward I. Ginns, Marzena Galdzicka
  • Publication number: 20090209624
    Abstract: In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.
    Type: Application
    Filed: October 24, 2006
    Publication date: August 20, 2009
    Applicant: University of Massachusetts
    Inventors: Edward I. Ginns, Gary R. Ostroff
  • Patent number: 6897022
    Abstract: Chromosomal regions comprising loci associated with susceptibility and resistance to bipolar affective disorder have been identified. Methods and compositions are provided for determining the contribution of these chromosomal regions to bipolar affective disorder in an affected family, for determining in an affected family a genotype associated with increased or decreased susceptibility or resistance to bipolar illness, and for assessing an increased or decreased risk of developing bipolar illness for a tested individual from an affected family.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: May 24, 2005
    Assignees: University of Miami, The United States of America as represented by the Secretary of Health & Human Services
    Inventors: Edward I. Ginns, Janice A. Egeland, Steven M. Paul
  • Publication number: 20040248086
    Abstract: Chromosomal regions comprising loci associated with susceptibility and resistance to bipolar affective disorder have been identified. Methods and compositions are provided for determining the contribution of these chromosomal regions to bipolar affective disorder in an affected family, for determining in an affected family a genotype associated with increased or decreased susceptibility or resistance to bipolar illness, and for assessing an increased or decreased risk of developing bipolar illness for a tested individual from an affected family.
    Type: Application
    Filed: June 13, 2001
    Publication date: December 9, 2004
    Inventors: Edward I. Ginns, Janice A. Egeland, Steven M. Paul
  • Patent number: 6566061
    Abstract: Nucleic acid sequences within the q13 region of the X chromosome having polymorphisms associated with neuropsychiatric disorders and associated conditions are disclosed herein. One polymorphism occurs within the coding region of the HOPA gene and introduces a four amino acid insertion into a putative OPA domain, a domain which has been shown to be involved in tissue specific expression. Compositions including nucleic acids having these polymorphisms and antibodies to polymorphic regions within proteins encoded in the PCTG4 region are provided. Methods of using the information and nucleic acid sequences disclosed herein for the diagnosis and assessment of pathologies associated with neuropsychiatric disorders and associated conditions are also provided.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: May 20, 2003
    Assignees: The University of Iowa, as represented by the University of Iowa Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert A. Philibert, Edward I. Ginns, Lynn Delisi
  • Publication number: 20030013178
    Abstract: The present invention provides the discovery and isolation of the nucleotide sequence of the human clk2, the human propin1, and the human cote1 genes that are located within the glucocerebrosidase gene locus. Also provided by the present invention are proteins or polypeptides encoded by those genes, nucleic acids encoding those polypeptides, and antibodies to those proteins. Further provided by the present invention are nucleic acids of the same apparent molecular size as the propin1 and cote1 gene regions and which have the same restriction pattern as the wild-type genes.
    Type: Application
    Filed: February 22, 2001
    Publication date: January 16, 2003
    Applicant: Department of Health and Human Sevices, c/o National Institutes of Health
    Inventors: Edward I. Ginns, Ellen Sidransky, Suzanne L. Winfield, Nahid Tayebi, Brian M. Martin
  • Publication number: 20020192655
    Abstract: Chromosomal regions comprising loci associated with susceptibility and resistance to bipolar affective disorder have been identified. Methods and compositions are provided for determining the contribution of these chromosomal regions to bipolar affective disorder in an affected family, for determining in an affected family a genotype associated with increased or decreased susceptibility or resistance to bipolar illness, and for assessing an increased or decreased risk of developing bipolar illness for a tested individual from an affected family.
    Type: Application
    Filed: June 13, 2001
    Publication date: December 19, 2002
    Inventors: Edward I. Ginns, Janice A. Egeland, Steven M. Paul
  • Patent number: 6074864
    Abstract: Glucocerebrosidase produced by recombinant methods and having use for treatment of Gaucher's disease is disclosed. A cDNA for encoding the specific protein is taught along with the method of preparing the construct used to produce the protein.
    Type: Grant
    Filed: January 13, 1994
    Date of Patent: June 13, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Edward I. Ginns, Brian Martin, Kara A. Maysak, William K. Eliason, Mary E. LaMarca